Candidiasis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Candidiasis Therapeutics Market is segmented by Route of Administration (Injection, Ointment, and Oral), Drug Type (Polyene, Azole, Echinocandin, and Other Drug Types), Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, and Systemic Candidiasis), End-users (Hospitals and Clinics, Retail Pharmacies, and Other End-users), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.

Candidiasis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Candidiasis Therapeutics Industry Overview

The Candidiasis Therapeutics market is competitive and consists of several major players. In terms of market share, a few major players dominate the market. Some prominent players launch new products, while others engage in product development and clinical trials. The competitive landscape includes an analysis of several companies which hold most of the market shares and are well known. Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others.

Candidiasis Therapeutics Market Leaders

  1. Basilea Pharmaceuticals

  2. Astellas

  3. SCYNEXIS, Inc.

  4. Pfizer Inc.

  5. Viatris Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Candidiasis Therapeutics Market Concentration

Candidiasis Therapeutics Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?